{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:35:54Z","timestamp":1790361354977,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T00:00:00Z","timestamp":1514592000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00228-017-2407-z","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T23:13:10Z","timestamp":1514589190000},"page":"627-636","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase\u00ae."],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3481-3539","authenticated-orcid":false,"given":"Kristian","family":"Svendsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mollie","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedvig","family":"Nordeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,30]]},"reference":[{"key":"2407_CR1","unstructured":"European Medicines Agency. Assessment report. Metoclopramide only containing procucts; December 2013. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Metoclopramide_31\/WC500160356.pdf\n\n (accessed 20 December 2016)."},{"key":"2407_CR2","unstructured":"Food and Drug Administration. Medication Guide Reglan (REG-lan) Tablets (metoclopramide tablets). NDA 017854\/S-052 NDA 021793\/S-005, June 2009. \nhttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/017854s052\n\n,021793s005medguide.pdf (accessed 20 December 2016)"},{"issue":"3","key":"2407_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/0091270007312258","volume":"48","author":"C Kenney","year":"2008","unstructured":"Kenney C, Hunter C, Davidson A, Jankovic J (2008) Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 48(3):379\u2013384. \nhttps:\/\/doi.org\/10.1177\/0091270007312258","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2407_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/ncpgasthep0442","volume":"3","author":"PJ Pasricha","year":"2006","unstructured":"Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J (2006) Drug insight: from disturbed motility to disordered movement\u2014a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 3(3):138\u2013148. \nhttps:\/\/doi.org\/10.1038\/ncpgasthep0442","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"1","key":"2407_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2036.2009.04189.x","volume":"31","author":"AS Rao","year":"2010","unstructured":"Rao AS, Camilleri M (2010) Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 31(1):11\u201319. \nhttps:\/\/doi.org\/10.1111\/j.1365-2036.2009.04189.x","journal-title":"Aliment Pharmacol Ther"},{"key":"2407_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7916\/D88P5Z71.","volume":"12","author":"O Waln","year":"2013","unstructured":"Waln O, Jankovic J (2013) An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) 12:161\u2013172. \nhttps:\/\/doi.org\/10.7916\/D88P5Z71.","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"1","key":"2407_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/head.12712","volume":"56","author":"S Wijemanne","year":"2016","unstructured":"Wijemanne S, Jankovic J, Evans RW (2016) Movement disorders from the use of metoclopramide and other antiemetics in the treatment of migraine. Headache 56(1):153\u2013161. \nhttps:\/\/doi.org\/10.1111\/head.12712","journal-title":"Headache"},{"issue":"8","key":"2407_CR8","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/pds.1397","volume":"16","author":"S Kapland","year":"2007","unstructured":"Kapland S, Staffa J, Dal Pan G (2007) Duration of therapy with metoclopramide: a prescription claims data study. Pharmacoepidemiol Drug Saf 16(8):878\u2013881. \nhttps:\/\/doi.org\/10.1002\/pds.1397","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2407_CR9","unstructured":"Food and Drug Administration. Metoclopramide information. \nhttp:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm220099.htm\n\n (accessed 20 December 2016)."},{"issue":"1","key":"2407_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12884-015-0746-2","volume":"15","author":"K Heitmann","year":"2015","unstructured":"Heitmann K, Holst L, Lupattelli A, Maltepe C, Nordeng H (2015) Treatment of nausea in pregnancy: a cross-sectional multinational web-based study of pregnant women and new mothers. BMC pregnancy and childbirth 15(1):321. \nhttps:\/\/doi.org\/10.1186\/s12884-015-0746-2","journal-title":"BMC pregnancy and childbirth"},{"issue":"1","key":"2407_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0028-2243(85)90160-1","volume":"19","author":"A Kauppila","year":"1985","unstructured":"Kauppila A, Anunti P, Kivinen S, Koivisto M, Ruokonen A (1985) Metoclopramide and breast feeding: efficacy and anterior pituitary responses of the mother and the child. Eur J Obstet Gynecol Reprod Biol 19(1):19\u201322. \nhttps:\/\/doi.org\/10.1016\/0028-2243(85)90160-1","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2407_CR12","doi-asserted-by":"crossref","unstructured":"Matok I, Perlman A (2014) Metoclopramide in pregnancy: no association with adverse fetal and neonatal outcomes. Evid Based Med.:ebmed-2013-101654","DOI":"10.1136\/eb-2013-101654"},{"issue":"15","key":"2407_CR13","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1001\/jama.2013.278343","volume":"310","author":"B Pasternak","year":"2013","unstructured":"Pasternak B, Svanstrom H, Molgaard-Nielsen D, Melbye M, Hviid A (2013) Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. JAMA 310(15):1601\u20131611. \nhttps:\/\/doi.org\/10.1001\/jama.2013.278343","journal-title":"JAMA"},{"key":"2407_CR14","unstructured":"WHO Collaborating Center for International Drug Monitoring. Caveat Document. Accompanying statment to data released from the Uppsala Monitoring Centre, WHO Collaboratoring Centre for International Drug Monitoring, Uppsala; 2015. [Available from: \nhttps:\/\/www.who-umc.org\/media\/1417\/umc_caveat_201605.pdf\n\n] (accessed 5. October 2017)."},{"key":"2407_CR15","unstructured":"Uppsala Monitoring Centre. Vigibase FAQs [Available from: \nhttps:\/\/www.who-umc.org\/vigibase\/vigibase\/know-more-about-vigibase\/\n\n]"},{"key":"2407_CR16","unstructured":"Food and Drug Administration. FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs [press release]. February 2009. \nhttps:\/\/wayback.archive-it.org\/7993\/20170112033201\/http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2009\/ucm149533.htm\n\n (accessed 15 April 2017)"},{"key":"2407_CR17","unstructured":"European Medicines Agency. Guideline on the use of statistical signal detection methods on the eudravigilance data analysis system. EMEA\/106464\/2006 rev.1, London; 2008. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2009\/11\/WC500011434.pdf\n\n (accessed 20 December 2016)"},{"issue":"6","key":"2407_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","volume":"38","author":"G Candore","year":"2015","unstructured":"Candore G, Juhlin K, Manlik K, Thakrar B, Quarcoo N, Seabroke S, Wisniewski A, Slattery J (2015) Comparison of statistical signal detection methods within and across spontaneous reporting databases. Drug Saf 38(6):577\u2013587. \nhttps:\/\/doi.org\/10.1007\/s40264-015-0289-5","journal-title":"Drug Saf"},{"issue":"8","key":"2407_CR19","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/npp.2011.55","volume":"36","author":"MG Woerner","year":"2011","unstructured":"Woerner MG, Correll CU, Alvir JM, Greenwald B, Delman H, Kane JM (2011) Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naive patients. Neuropsychopharmacology 36(8):1738\u20131746. \nhttps:\/\/doi.org\/10.1038\/npp.2011.55","journal-title":"Neuropsychopharmacology"},{"key":"2407_CR20","unstructured":"Norwegian Prescription Database. Metoclopramide. Users per 1000 during 2015. \nhttp:\/\/www.norpd.no\/Prevalens.aspx\n\n (accessed 20 December 2016)."},{"key":"2407_CR21","unstructured":"The National Board of Health and Welfare. Statistical database. Metoclopramide. Users per 1000 during (2015) Stockholm:2016 \nhttp:\/\/www.socialstyrelsen.se\/statistik\/statistikdatabas\/lakemedel\n\n (accessed 20 December 2016"},{"issue":"6","key":"2407_CR22","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/ajg.2012.300","volume":"108","author":"ED Ehrenpreis","year":"2013","unstructured":"Ehrenpreis ED, Deepak P, Sifuentes H, Devi R, Du H, Leikin JB (2013) The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Am J Gastroenterol 108(6):866\u2013872. \nhttps:\/\/doi.org\/10.1038\/ajg.2012.300","journal-title":"Am J Gastroenterol"},{"key":"2407_CR23","first-page":"131","volume":"4","author":"E Ehrenpreis","year":"2015","unstructured":"Ehrenpreis E, Krishnan A, Alexoff A, Smith D, Wilensky S (2015) A survey of lawsuits filed for the complaint of tardive dyskinesia following treatment with metoclopramide. Clin Pharmacol Biopharm 4:131","journal-title":"Clin Pharmacol Biopharm"},{"key":"2407_CR24","unstructured":"Sweden MPA (October 2016) Summary of product characteristics. Primperan tablet, Uppsala \nhttps:\/\/lakemedelsverket.se\/LMF\/Lakemedelsinformation\/?nplid=19720825000013&type=product\n\n (accessed 20 December 2016"},{"issue":"1","key":"2407_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/01.nrl.0000038585.58012.97","volume":"9","author":"HH Fernandez","year":"2003","unstructured":"Fernandez HH, Friedman JH (2003) Classification and treatment of tardive syndromes. Neurologist 9(1):16\u201327. \nhttps:\/\/doi.org\/10.1097\/01.nrl.0000038585.58012.97","journal-title":"Neurologist"},{"issue":"3","key":"2407_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1600-0447.1997.tb10153.x","volume":"96","author":"J Os van","year":"1997","unstructured":"van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R (1997) Tardive dyskinesia: who is at risk? Acta Psychiatr Scand 96(3):206\u2013216. \nhttps:\/\/doi.org\/10.1111\/j.1600-0447.1997.tb10153.x","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"2407_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/01.jcp.0000144888.43449.54","volume":"24","author":"I Wonodi","year":"2004","unstructured":"Wonodi I, Adami HM, Cassady SL, Sherr JD, Avila MT, Thaker GK (2004) Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J Clin Psychopharmacol 24(6):592\u2013598. \nhttps:\/\/doi.org\/10.1097\/01.jcp.0000144888.43449.54","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"2407_CR28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1586\/eem.10.41","volume":"5","author":"A Lee","year":"2010","unstructured":"Lee A, Kuo B (2010) Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab 5(5):653\u2013662. \nhttps:\/\/doi.org\/10.1586\/eem.10.41","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"5","key":"2407_CR29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00228-016-2012-6","volume":"72","author":"K Heitmann","year":"2016","unstructured":"Heitmann K, Solheimsnes A, Havnen GC, Nordeng H, Holst L (2016) Treatment of nausea and vomiting during pregnancy\u2014a cross-sectional study among 712 Norwegian women. Eur J Clin Pharmacol 72(5):593\u2013604. \nhttps:\/\/doi.org\/10.1007\/s00228-016-2012-6","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"2407_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068938","volume":"8","author":"G Karimi","year":"2013","unstructured":"Karimi G, Star K, Noren GN, Hagg S (2013) The impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilance. PLoS One 8(7):e68938. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0068938","journal-title":"PLoS One"},{"issue":"5","key":"2407_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29(5):385\u2013396. \nhttps:\/\/doi.org\/10.2165\/00002018-200629050-00003","journal-title":"Drug Saf"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-017-2407-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2407-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2407-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T04:54:31Z","timestamp":1523336071000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-017-2407-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,30]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2407"],"URL":"https:\/\/doi.org\/10.1007\/s00228-017-2407-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,30]]}}}